<DOC>
	<DOC>NCT01980030</DOC>
	<brief_summary>This is a Phase I/II multicenter study which aims to assess the toxicity profile of Romiplostim in patients with transfusion-dependent thrombocytopenia after allogeneic HSCT. A total of 24 patients with transfusion-dependent thrombocytopenia after allogeneic HSCT will be included. The main endpoint is the incidence and severity of adverse events.</brief_summary>
	<brief_title>Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Subjects must be ≥ 18 years, willing and able to sign informed consent Patients could have been transplanted for hematological disorder (malignant or nonmalignant) excepted myelodysplastic syndromes patients and had received either a myeloablative or a reduced intensity conditioning. All sources of allogeneic stem cells are allowed. Prolonged (&gt; 2 months) transfusiondependent thrombocytopenia Screenings mean platelet count≤ 20 x giga/L or screenings mean platelet count ≤ 50 x giga/L with a history of bleeding. (ECOG) performance status of 02 Adequate liver function Serum creatinine ≤ 176.8 μmol/L Bone marrow aspirate with cytogenetics within 6 days of the first dose of romiplostim Written informed consent Relapse/progression of hematological malignancy (marrow examination required) Noncontrolled acute and/or chronic graft versus host disease (GvHD) Active or uncontrolled infections Cardiac pathology Thrombosis Pregnancy or breast feeding Received interleukin11 (IL11) within 4 weeks of screening or previously received any thrombopoietic growth factor Patients on anticoagulant therapy Receipt or planned receipt of Pegylated Granulocyte Colony Stimulating Factor (PEGGCSF), or Granulocyte macrophagecolony stimulating factor (GMCSF) within 4 weeks of the first dose of investigational product Subject not using adequate contraceptive precautions, in the judgment of the investigator Sensitivity to any Escherichia coliderived product Inability to comply with study procedures. Subject currently is enrolled in or has not yet completed 30 days since ending other investigational device or drug study No medical insurance in the French Health system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>